[Cefixime. Microbiologic, kinetic and clinical profile].
The microbiological, kinetic and clinical profile of cefixime, a IIIrd generation cephalosporin, administered orally, is presented. Cefixime is highly active versus Gram-negative aerobic bacteria while, with respect to Gram-positive bacteria, it is only active against Str. pneumoniae, Str. pyogenes, Str. agalactiae, and Str. bovis. It has no action against anaerobics. Endowed with good kinetics, cefixime possesses a favourable tissue distribution. Cefixime is highly indicated in infections of the upper and lower airways where the aethiology is prevalently due to Str. pneumoniae, H. influenzae and B. catarrhalis, that are extremely sensitive to the antibiotic. It is concluded that the therapeutic armamentarium has been enriched by a new, highly active antibiotic that, administered in a monodese/die, ca satisfy patient compliance.
Di Nola
F
F
Ospedale Amedeo di Savoia, Torino.
Arione
R
R
Bramato
C
C
D000818:Animals; D001419:Bacteria / Q000187:drug effects; D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006069:Gonorrhea / Q000188:drug therapy; D006801:Humans; D008826:Microbial Sensitivity Tests; D010033:Otitis Media / Q000188:drug therapy; D010612:Pharyngitis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D014069:Tonsillitis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D020682:Cefixime; D002439:Cefotaxime
Cefixime. Profilo microbiologico, cinetico e clinico.